## **Special Issue**

# Emerging Insights into HIV: Second Edition

#### Message from the Guest Editors

This Special Issue aims to provide a comprehensive and up-to-date overview of the latest research and developments in the field of HIV pathogenesis and treatment. Moreover, it seeks to gather cutting-edge research and insights that contribute to the ongoing efforts to combat HIV, advance our understanding of HIV infection, and address global challenges, with a focus on global health equity. Original research articles and reviews that align with the aim and scope of this Special Issue are welcome. Research areas may include, but are not limited to, the following: antiretroviral treatment and toxicities; novel antiretroviral treatment; HIV/HCV co-infection: HIV and COVID-19: HIV and comorbidities: AIDS-related illness and opportunistic infections: and HIV cures. Manuscripts should adhere to the journal's guidelines for formatting and referencing.

#### **Guest Editors**

Dr. Konstantinos Protopapas

Dr. Antonios Papadopoulos

Dr. Charalampos D. Moschopoulos

#### Deadline for manuscript submissions

31 January 2026



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/247661

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





### **About the Journal**

#### Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

#### Editor-in-Chief

#### Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

#### **Author Benefits**

#### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).